Therapeutic efficacy
Evaluate small molecules, degraders, antibodies, and other candidate interventions against arthritis progression.
IMMUNOLOGY & INFLAMMATION MODEL
Collagen-Induced Arthritis (CIA) Mouse Model
The documented CIA platform uses DBA/1 mice and type II collagen immunization for rheumatoid-arthritis pharmacology studies involving T- and B-cell biology.
Documented efficacy programs include small molecules, degraders, and antibody-based interventions with serial clinical, immune, and histopathology readouts.
MODEL OVERVIEW
A data-rich arthritis model for immune-mediated pharmacology.
CIA studies in DBA/1 mice can combine longitudinal arthritis scoring and paw-thickness measurements with serum immunoglobulins, inflammatory cytokines, immune-cell profiling, and joint histopathology.
Therapeutic areaRheumatoid arthritis
Species / strainDBA/1 mouse
Model formatCollagen-induced arthritis
Typical useEfficacy, Immune profiling
TYPICAL APPLICATIONS
What this model can support.
Humoral response
Serial serum total IgG and anti-type II collagen IgG1 measurements can be incorporated into the study design.
Immune-cell profiling
Spleen FACS analysis can quantify T-cell, B-cell, myeloid, neutrophil, plasma-cell, and related immune populations.
Joint pathology
Histopathology workflows can include HE, TRAP, and Safranin O/Fast Green staining for joint and bone changes.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Disease activity
Arthritis score, body weight, and hind-paw thickness across induction and efficacy phases.
Immunoglobulins
Serum total IgG and anti-type II collagen IgG1 by ELISA.
Cytokines & FACS
Inflammatory cytokines and protocol-defined spleen immune-cell populations by flow cytometry.
Histopathology
HE, TRAP, Safranin O/Fast Green, and quantitative histology scoring where included.
The exact induction schedule, treatment window, reference arm, sampling plan, and pathology package are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- Candidate mechanism and immune target
- Induction and treatment schedule
- Prophylactic or therapeutic study design
- Clinical scoring and paw-thickness schedule
- Serum, FACS, cytokine, and tissue endpoints
- Histology staining and quantitative analysis plan
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a CIA study.Required fields are marked with an asterisk(*).